5 results
8-K
EX-99.1
RLYB
Rallybio Corp
15 Mar 22
Rallybio Reports Fourth Quarter and Full Year 2021 Financial Results
8:30am
recently initiated a Phase 1 healthy volunteer study of RLYB116, our C5 inhibitor in development for the treatment of patients with PNH and gMG
S-1
EX-10.1
RLYB
Rallybio Corp
2 Jul 21
IPO registration
4:28pm
employee or volunteer or any other Person. Prophylix is in compliance with the GDPR, both in its capacity as a data controller and a data processor
DRS/A
RLYB
Rallybio Corp
7 Jun 21
Draft registration statement (amended)
12:00am
: Investigational new drug; CTA: Clinical trial application; HV: Healthy volunteer
RLYB211 and RLYB212 for the Prevention of FNAIT
FNAIT is a potentially life … trial application; HV: Healthy volunteer
Prevention of FNAIT
Our most advanced program is targeting the prevention of FNAIT, a potentially life
DRS
RLYB
Rallybio Corp
27 Apr 21
Draft registration statement
12:00am
of concept; IND: Investigational new drug; CTA: Clinical trial application; HV: Healthy volunteer
RLYB211 and RLYB212 for the Prevention of FNAIT
FNAIT … /phosphodiesterase 1; PoC: Proof of concept; IND: Investigational new drug; CTA: Clinical trial application; HV: Healthy volunteer
Prevention of FNAIT
Our
DRS
EX-10.1
RLYB
Rallybio Corp
27 Apr 21
Draft registration statement
12:00am
employee or volunteer or any other Person. Prophylix is in compliance with the GDPR, both in its capacity as a data controller and a data processor
- Prev
- 1
- Next